Assessment of cognitive function in female rheumatoid arthritis patients: associations with cerebrovascular pathology, depression and anxiety.
Aged
Antirheumatic Agents
/ administration & dosage
Anxiety
/ complications
Arthritis, Rheumatoid
/ complications
Biological Products
/ administration & dosage
Carotid Intima-Media Thickness
Case-Control Studies
Cognition
Cognitive Dysfunction
/ complications
Cross-Sectional Studies
Depression
/ complications
Female
Humans
Mental Status and Dementia Tests
Methotrexate
/ administration & dosage
Middle Aged
Middle Cerebral Artery
/ diagnostic imaging
Biological therapy
Carotid artery
Cerebrovascular disease
Cognitive dysfunction
Methotrexate
Rheumatoid arthritis
Transcranial Doppler
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
21
07
2019
accepted:
17
09
2019
pubmed:
27
9
2019
medline:
1
4
2021
entrez:
27
9
2019
Statut:
ppublish
Résumé
We assessed cognitive function of female rheumatoid arthritis (RA) patients and analyze the determinants, with special focus on cerebrovascular morphology. Sixty methotrexate (MTX-) or biologic-treated RA patients and 39 healthy controls were included in a cross-sectional study. Smoking habits, alcohol intake and time spent in education were recorded. Standard measures were performed to assess cognitive function (Montreal Cognitive Assessment, MOCA; Trail Making Test, TMT; Victoria Stroop Test, VST; Wechsler Adult Intelligence Scale, WAIS; Benton Visual Retention test, BVRT), depression (Beck Depression Inventory, BDI), anxiety (State-Trait Anxiety Inventory, STAIT/S) and general health status (Short Form 36, SF-36). Mean disease activity (28-joint Disease Activity Score, mDAS28; erythrocyte sedimentation rate, mESR; C-reactive protein, mCRP) of the past 12 months was calculated; anti-cyclic citrullinated peptide (CCP) and rheumatoid factor (RF) were assessed. Cerebral vascular lesions and atrophy, carotid intima-media thickness (cIMT) and plaques, as well as median cerebral artery (MCA) circulatory reserve capacity (CRC) were assessed by brain magnetic resonance imaging (MRI), carotid ultrasound and transcranial Doppler, respectively. Cognitive function tests showed impairment in RA vs controls. Biologic- vs MTX-treated subgroups differed in TMT-A. Correlations were identified between cognitive function and depression/anxiety tests. WAIS, STAIS, STAIT and BDI correlated with most SF-36 domains. Numerous cognitive tests correlated with age and lower education. Some also correlated with disease duration, mESR and mDAS28. Regarding vascular pathophysiology, cerebral vascular lesions were associated with VST-A, carotid plaques with multiple cognitive parameters, while MCA and CRC with MOCA, BVRT and BDI. RA patients have significant cognitive impairment. Cognitive dysfunction may occur together with or independently of depression/anxiety. Older patients and those with lower education are at higher risk to develop cognitive impairment. Cognitive screening might be a useful tool to identify subgroups to be further investigated for cerebrovascular pathologies.
Identifiants
pubmed: 31555886
doi: 10.1007/s00296-019-04449-8
pii: 10.1007/s00296-019-04449-8
doi:
Substances chimiques
Antirheumatic Agents
0
Biological Products
0
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
529-540Subventions
Organisme : European Union
ID : TAMOP-4.2.4.A/2-11/1-2012-0001
Organisme : European Union
ID : GINOP-2.3.2-15-2016-00015
Organisme : European Union
ID : GINOP-2.3.2-15-2016-00050
Références
Ann Rheum Dis. 2017 Jan;76(1):17-28
pubmed: 27697765
Nat Commun. 2018 Jun 8;9(1):2243
pubmed: 29884867
Vojnosanit Pregl. 2011 Jun;68(6):481-8
pubmed: 21818914
Arthritis Res Ther. 2017 Sep 26;19(1):213
pubmed: 28950911
Clin Rheumatol. 2007 May;26(5):753-8
pubmed: 17332982
Methods Find Exp Clin Pharmacol. 2004 Jun;26(5):339-43
pubmed: 15319812
Best Pract Res Clin Rheumatol. 2002 Dec;16(5):707-22
pubmed: 12473269
Arthritis Res Ther. 2012 Dec 04;14(6):R263
pubmed: 23211089
Autoimmun Rev. 2010 Mar;9(5):A325-9
pubmed: 20026258
J Rheumatol. 2008 Mar;35(3):398-406
pubmed: 18203326
J Clin Rheumatol. 2017 Dec;23(8):425-434
pubmed: 28221313
Ann N Y Acad Sci. 2007 Jun;1108:349-58
pubmed: 17893998
Stroke. 2001 Aug;32(8):1811-7
pubmed: 11486110
Semin Arthritis Rheum. 2014 Oct;44(2):123-30
pubmed: 24973898
J Gerontol Nurs. 2012 Sep;38(9):33-42
pubmed: 22897128
Arch Cardiovasc Dis. 2010 Apr;103(4):253-61
pubmed: 20656636
Pain. 2001 Jan;89(2-3):275-83
pubmed: 11166484
J Neurol Sci. 2017 Feb 15;373:285-288
pubmed: 28131207
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Clin Exp Rheumatol. 2018 Sep-Oct;36(5):856-861
pubmed: 29652660
J Neurosci. 2008 Mar 26;28(13):3474-8
pubmed: 18367613
J Health Psychol. 2013 Oct;18(10):1353-9
pubmed: 23188915
Arthritis Rheum. 2013 Feb;65(2):325-33
pubmed: 23238986
Arthritis Rheum. 2004 Jun 15;51(3):408-12
pubmed: 15188326
Arthritis Care Res (Hoboken). 2013 Mar;65(3):481-6
pubmed: 22899659
Arthritis Care Res (Hoboken). 2012 Aug;64(8):1144-50
pubmed: 22505279
Ultrasound Med Biol. 2014 Jan;40(1):78-89
pubmed: 24120415
Clin J Pain. 2010 Oct;26(8):683-9
pubmed: 20862788
J Rheumatol. 2013 Mar;40(3):236-43
pubmed: 23322467
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Sci Rep. 2016 Jan 25;6:19556
pubmed: 26806793
Arthritis Care Res (Hoboken). 2018 Jan;70(1):39-52
pubmed: 28371512
Autoimmun Rev. 2015 Dec;14(12):1116-22
pubmed: 26238502
Neuropsychopharmacology. 2015 Jan;40(2):502-12
pubmed: 25103178
Pain. 2002 Nov;100(1-2):141-53
pubmed: 12435467
Ann N Y Acad Sci. 2010 Oct;1207:155-62
pubmed: 20955439